Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00921414 |
Recruitment Status :
Completed
First Posted : June 16, 2009
Last Update Posted : April 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mantle Cell Lymphoma | Drug: Rituximab Other: Watch and wait | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 299 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | September 2008 |
Actual Study Completion Date : | February 2017 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
observation : 3 years maintenance period with assesments and surveillance every 2 months
|
Other: Watch and wait
No treatment patient follow-up every 2 months during 3 years
Other Name: observation |
Experimental: 2
maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
|
Drug: Rituximab
2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
Other Name: Mabthera® |
- event-free survival (EFS) post Rituximab maintenance therapy [ Time Frame: EFS post 4 years after maintenance ]
- duration of PFS of the entire group of patients. [ Time Frame: Safety/efficacy of maintenance treatment ]
- duration of OS of the entire group of patients [ Time Frame: safety/efficacy of treatment ]
- complete, partial and overall response rate after induction with R-DHAP and after ASCT. [ Time Frame: safety/efficacy of all the treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- mantle cell lymphoma
- Initial immunophenotyping with CD20 and CD5.
- CD20+.
- t (11;14) by karyote, FISH, molecular biology or immunohistochemistry (Bcl-1)
- Patient no previous treated.
- At least one tumor site accessible for assessment
- Aged > 18 years < 65
- ECOG < or = 2.
- No other neoplasms apart from resected basal cell carcinoma or in situ carcinoma.
- signed informed consent
- FEVG 50%
Exclusion Criteria:
- other type of lymphoma
- ECOG > or = 3
- relapse
- serology VIH + Hepatite +
- diabetis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00921414
France | |
Regional University Hospital | |
Nantes, France, 44093 |
Principal Investigator: | Steven LE GOUILL, MD | French Innovative Leukemia Organisation |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | French Innovative Leukemia Organisation |
ClinicalTrials.gov Identifier: | NCT00921414 |
Other Study ID Numbers: |
Manteau 2007 SJ "LYMA" |
First Posted: | June 16, 2009 Key Record Dates |
Last Update Posted: | April 27, 2018 |
Last Verified: | April 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Mantle cell lymphoma R DHAP ASCT Rituximab Maintenance |
Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Lymphoma, Non-Hodgkin Rituximab Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |